Pharmacokinetics of Lumiracoxib in Plasma and Synovial Fluid
- 137 Downloads
umiracoxib is a new cyclo-oxygenase-2 (COX-2) selective inhibitor in development for the treatment of rheumatoid arthritis, osteoarthritis and acute pain.
To investigate the pharmacokinetics of lumiracoxib in plasma and knee joint synovial fluid from patients with rheumatoid arthritis.
Open-label multiple-dose study evaluating the steady-state pharmacokinetics of lumiracoxib in plasma and synovial fluid after 7 days of treatment with lumiracoxib 400mg once daily.
Males and females aged 18–75 years with rheumatoid arthritis, having moderate to significant synovial fluid effusion of the knee.
Following a 7-day washout period for previous nonsteroidal anti-inflammatory drugs, 22 patients (17 female, 5 male) received lumiracoxib 400mg once daily for seven consecutive days. On day 7, following an overnight fast, a final dose of lumiracoxib was administered and serial blood and synovial fluid samples were collected for up to 28 hours. Lumiracoxib and its metabolites (4′-hydroxy-lumiracoxib and 5-carboxy-4′-hydroxy-lumiracoxib) were measured by validated high performance liquid chromatography-mass spectrometry methods. The steady-state pharmacokinetics of lumiracoxib were evaluated in plasma and synovial fluid by both a population pharmacokinetic model and noncompartmental analysis.
Lumiracoxib was rapidly absorbed (peak plasma concentration at 2 hours) and the terminal elimination half-life in plasma was short (6 hours). Lumiracoxib concentrations were initially higher in plasma than in synovial fluid; however, from 5 hours after administration until the end of the 28-hour assessment period, concentrations of lumiracoxib were higher in synovial fluid than in plasma. Peak drug concentration in synovial fluid occurred 3–4 hours later than the peak plasma concentration. The mean steady-state trough concentration of lumiracoxib in synovial fluid (454 μg/L) was approximately three times higher than the mean value in plasma (155 μg/L), and the area under the concentration-time curve from 12 to 24 hours after administration was 2.6-fold higher for synovial fluid than for plasma. Median lumiracoxib protein binding was similar in plasma and synovial fluid (range 97.9–98.3%). Concentrations of 4′-hydroxy-lumiracoxib, the active COX-2 selective metabolite, remained low in comparison with parent drug in both plasma and synovial fluid. The concentration of lumiracoxib in synovial fluid at 24 hours after administration would be expected to result in substantial inhibition of prostaglandin E2 formation.
The kinetics of distribution of lumiracoxib in synovial fluid are likely to extend the therapeutic action of the drug beyond that expected from plasma pharmacokinetics. These data support the use of lumiracoxib in a once-daily regimen for the treatment of rheumatoid arthritis.
KeywordsSynovial Fluid Etodolac Tenoxicam Tiaprofenic Acid Population Pharmacokinetic Model
- 6.Gu H, Rodriguez L, Mangold J. In vitro determination of cytochrome P450 involvement in COX189 hepatic metabolism and drug-drug interaction potential. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2000. (Data on file)Google Scholar
- 7.Mangold JB, Gu H, Rodriguez LC, et al. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects [abstract]. Drug Metab Rev 2002; 34 (1 Suppl.): 141Google Scholar
- 8.Marshall PJ, Berry JC. Inhibition of thromboxane B2 and prostaglandin E2 from human whole blood in vitro by CGS 35189 and its metabolites. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2002. (Data on file)Google Scholar
- 9.Rordorf C, Scott G, Milosavljev S, et al. Steady state pharmacokinetics, pharmacodynamics, safety and tolerability of COX189 in healthy subjects [abstract]. Ann Rheum Dis 2002; 61 (1 Suppl.): 420Google Scholar
- 10.Scott G, Rordorf C, Milosavljev S, et al. Pharmacokinetics and pharmacodynamics of COX189 in patients with knee or hip primary osteoarthritis [abstract]. Ann Rheum Dis 2002; 61 (1 Suppl.): 128Google Scholar
- 11.Scott G, Branson J, Milosavljev S, et al. Lumiracoxib demonstrates dose-proportional and time-independent pharmacokinetics in patients with osteoarthritis of the knee [abstract]. Ann Rheum Dis 2003; 62 (1 Suppl.): 267Google Scholar
- 12.Scott G, Rordorf C, Milosavljev S, et al. Multiple-dose lumiracoxib shows rapid absorption and COX-2 selectivity without accumulation in patients with rheumatoid arthritis [abstract]. In: Tulunay FC, Orme M, editors. European collaboration: towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin: Springer-Verlag, 2003: 124Google Scholar
- 14.Dawson J, Jagher B, Toscano KT, et al. Lumiracoxib shows rapid distribution to inflamed sites in a rat tissue chamber model compared with rofecoxib and celecoxib [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 377Google Scholar
- 15.Weaver ML, Flood DJ, Kimble EF, et al. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclooxygenase-2 inhibitors [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 378Google Scholar
- 30.Schnitzer TJ, Geusens P, Hasler P, et al. Efficacy and safety of COX189 in osteoarthritis: a multi-national study [abstract]. Arthritis Rheum 2000; 43 (9 Suppl.): S336Google Scholar
- 31.Tannenbaum H, Berenbaum F, Reginster J-Y, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis. Epub 2004 Feb 27Google Scholar
- 38.Scott G, Rordorf C, Blood P, et al. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects [abstract]. Ann Rheum Dis 2002; 61 (1 Suppl.): 242Google Scholar
- 39.Fricke J, Zelenakas K, Jayawardene S, et al. Efficacy of COX189 compared to rofecoxib in the treatment of postoperative dental pain: a double-blind, randomized, placebo-controlled trial [abstract no. 953-P223]. World Congress on Pain (WCP); 2002 Aug 17–22; San DiegoGoogle Scholar
- 40.Weaver M, Milosavljev S. In vitro plasma protein binding of COX189 and three of its metabolites. East Hanover (NJ): Norvartis Pharmaceuticals Corporation, 2002. (Data on file)Google Scholar